MA-FORRESTER
25.6.2024 15:01:32 CEST | Business Wire | Press release
According to Forrester’s (Nasdaq: FORR) The Top 10 Emerging Technologies In 2024 report, generative AI (genAI) for visual content, genAI for language, TuringBots, and IoT security are the top emerging technologies that will deliver the most immediate ROI for businesses in 2024 and beyond.
With new technologies emerging seemingly every day, business and technology leaders need to time those investments based on value, risk, and potential payout timelines. Forrester organizes its top emerging technologies by benefit horizon to help with these decisions.
Emerging technologies that will offer significant benefits within the next two years:
- GenAI for visual content. Advanced machine learning models that generate images or video from text, audio, or video prompts, this technology will help firms generate visual content for marketing, experiences, and products.
- GenAI for language. GenAI for language is already delivering value in customer support and content creation but continues to advance at a blinding pace. It is accelerating many other technologies as it goes.
- TuringBots. Accelerated by advancements in genAI for language, these AI-powered software robots help developers build applications that deliver more than just code generation.
- IoT security. The proliferation of devices has led to an exponential explosion in security attacks, raising the importance of security for IoT devices. Vendors are competing and colliding in a rush to offer capabilities.
Midterm emerging technologies that will deliver benefits in the next two to five years:
- AI agents. The role of autonomous workplace assistants or AI agents has expanded beyond the back office and employee assistance to customer-facing automation. These AI agents will grow increasingly sophisticated to better understand and respond to nuance and context.
- Autonomous mobility. This technology will accelerate commercial and urban transportation ecosystem collaborations to orchestrate personalized mobility experiences for both customers and businesses.
- Edge intelligence. Advanced edge intelligence capabilities such as edge machine learning are still not yet common, even though many foundational elements like Apple foundation models are becoming available.
- Quantum security. This technology will overhaul security systems for on-premises and cloud compute, storage and network infrastructure, commercial off-the-shelf software, commercial software-as-a-service offerings, and in-house built software.
Emerging technologies that will take at least five more years to deliver tangible value for most firms and use cases:
- Extended reality (XR). Only 8% of US online adults own a virtual-reality headset, and just 16% have used an augmented-reality device or app. While XR is advancing in training and onboarding, companies are resisting investing in tools like these until they see broad adoption.
- Zero Trust edge (ZTE). ZTE technology has the potential to protect remote workers, retail outlets, and branch offices with embedded local security, but only a handful of true ZTE solutions exist today, and legacy devices add additional management complexity.
“Tech leaders must be able to identify the right use cases and quantify potential benefits, costs, and risks across multiple horizons,” says Brian Hopkins, Forrester VP, emerging tech portfolio. “They need to spread investments out, with shorter-term technologies delivering quick returns and longer-term bets requiring more effort, more foundational investment, and the capacity to manage more risk.”
Resources:
- Learn more about the top emerging technologies that will deliver ROI for enterprises.
- Read The Top 10 Emerging Technologies In 2024 report to gain insight into maturity trends, business value, important use cases, and risks associated with each technology (client access required).
- Register for a complimentary webinar that takes a deep dive into the 2024 list of emerging technologies and their use cases and benefits.
- Download Forrester’s complimentary guide for tech leaders to identify use cases and gain support for emerging technologies.
- Tech and data leaders can attend Forrester’s 2024 Technology & Innovation Summits in North America, EMEA, and Asia Pacific to learn how to align their IT strategy to their business goals to accelerate growth.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the center of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; more than 100 million real-time feedback votes; and the shared wisdom of our clients. To learn more, visit Forrester.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625049417/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
